news flash·2025-07-17 09:09Core Viewpoint - Tiger Medical (300347) announced that its investment platform, Tiger Equity, acquired a 4.762% stake in Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. and made additional investments of 10 million RMB and 40 million RMB to subscribe for newly issued shares of 2.86% and 2.65% respectively [1] Group 1 - As of the announcement date, Tiger Medical directly holds 3.41% of Lixin Pharmaceutical's equity through Tiger Equity, and indirectly holds 4.58% through fund shares [1] - Lixin Pharmaceutical plans to transfer 95.09% of its equity to Chia Tai Pharmaceutical Investment (Beijing) Group Co., Ltd., and Tiger Medical agrees to sell all its holdings for approximately 34.11 million USD [1] - This transaction is expected to enhance cash income, supplement cash flow, and promote the sustainable and healthy development of the company while maximizing shareholder value [1]